Savara Inc Operating Lease, Right-of-Use Asset, Amortization Expense
Savara Inc (SVRA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $113.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Savara Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $71.00K, a 77.50% increase year-over-year.
- Savara Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $42.00K, a 10.53% increase year-over-year.
- Savara Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $40.00K, a 5.26% increase year-over-year.
- Savara Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $40.00K, a 11.11% increase year-over-year.
- Savara Inc operating lease, right-of-use asset, amortization expense for fiscal 2025 was $158.00K, a 8.97% increase from fiscal 2024.
- Savara Inc operating lease, right-of-use asset, amortization expense for fiscal 2024 was $145.00K, a 47.96% increase from fiscal 2023.
- Savara Inc operating lease, right-of-use asset, amortization expense for fiscal 2023 was $98.00K, a 27.94% decline from fiscal 2022.
- Savara Inc operating lease, right-of-use asset, amortization expense for fiscal 2022 was $136.00K, a 41.13% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $113.00K 10-Q · filed 2026-08-11 | $153.00K derived: sum of 3 quarters · filed 2026-08-11 | $193.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $42.00K 10-Q · filed 2026-05-12 | $82.00K derived: sum of 2 quarters · filed 2026-05-12 | $122.00K derived: sum of 3 quarters · filed 2026-05-12 | $162.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $80.00K derived: sum of 2 quarters · filed 2026-03-13 | $120.00K derived: sum of 3 quarters · filed 2026-08-11 | $158.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $80.00K derived: sum of 2 quarters · filed 2026-08-11 | $118.00K 10-Q · filed 2025-11-12 | $156.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $78.00K 10-Q · filed 2026-08-11 | $116.00K derived: sum of 3 quarters · filed 2026-08-11 | $152.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $38.00K 10-Q · filed 2026-05-12 | $76.00K derived: sum of 2 quarters · filed 2026-05-12 | $112.00K derived: sum of 3 quarters · filed 2026-05-12 | $148.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $74.00K derived: sum of 2 quarters · filed 2026-03-13 | $110.00K derived: sum of 3 quarters · filed 2026-03-13 | $145.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $72.00K derived: sum of 2 quarters · filed 2025-11-12 | $107.00K 10-Q · filed 2025-11-12 | $141.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $71.00K 10-Q · filed 2025-08-13 | $105.00K derived: sum of 3 quarters · filed 2025-08-13 | $138.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $35.00K 10-Q · filed 2025-05-13 | $69.00K derived: sum of 2 quarters · filed 2025-05-13 | $102.00K derived: sum of 3 quarters · filed 2025-05-13 | $118.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $67.00K derived: sum of 2 quarters · filed 2025-03-27 | $83.00K derived: sum of 3 quarters · filed 2025-03-27 | $98.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $49.00K derived: sum of 2 quarters · filed 2024-11-12 | $64.00K 10-Q · filed 2024-11-12 | $99.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $31.00K 10-Q · filed 2024-08-12 | $66.00K derived: sum of 3 quarters · filed 2024-08-12 | $101.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $15.00K 10-Q · filed 2024-05-09 | $50.00K derived: sum of 2 quarters · filed 2024-05-09 | $85.00K derived: sum of 3 quarters · filed 2024-05-09 | $118.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $70.00K derived: sum of 2 quarters · filed 2024-03-07 | $103.00K derived: sum of 3 quarters · filed 2024-03-07 | $136.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $68.00K derived: sum of 2 quarters · filed 2023-11-09 | $101.00K 10-Q · filed 2023-11-09 | $236.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $66.00K 10-Q · filed 2023-08-10 | $201.00K derived: sum of 3 quarters · filed 2023-08-10 | $181.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-15 | $168.00K derived: sum of 2 quarters · filed 2023-05-15 | $148.00K derived: sum of 3 quarters · filed 2023-05-15 | $207.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $115.00K derived: sum of 2 quarters · filed 2023-03-30 | $174.00K derived: sum of 3 quarters · filed 2023-03-30 | $231.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $39.00K derived: sum of 2 quarters · filed 2022-11-10 | $96.00K 10-Q · filed 2022-11-10 | $149.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $116.00K 10-Q · filed 2022-08-11 | $169.00K derived: sum of 3 quarters · filed 2022-08-11 | $225.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $57.00K 10-Q · filed 2022-05-11 | $110.00K derived: sum of 2 quarters · filed 2022-05-11 | $166.00K derived: sum of 3 quarters · filed 2022-05-11 | $311.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $109.00K derived: sum of 2 quarters · filed 2022-03-30 | $254.00K derived: sum of 3 quarters · filed 2022-03-30 | $438.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $201.00K derived: sum of 2 quarters · filed 2021-11-12 | $385.00K 10-Q · filed 2021-11-12 | $565.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $329.00K 10-Q · filed 2021-08-12 | $509.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $184.00K 10-Q · filed 2021-05-13 | $364.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $699.00K 10-K · filed 2021-03-10 | ||
| 2019-09-30 | $519.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |